Company intelligence / Profile preview

X Med Ems

Durban, KwaZulu-Natal, South Africafacebook.com ↗

Ownership: Private
Development stage: Other

Overview

XMed is a commercial-stage biotech company offering a range of pharmaceutical and performance-enhancing products including peptides, hormones, and small molecules. The company appears to focus on both clinical development services and direct-to-consumer sales of compounds such as semaglutide, human growth hormone, anabolic steroids like stanozolol and superdrol, dopamine agonists like cabergoline, and thyroid hormones. There is no public information about clinical trial results; the business model seems to be more service/product-oriented than R&D-driven.

Therapeutic areas: EndocrinologyNeurology
Modalities: Small moleculeProteinHormonePeptides
Industry: Biotech

Beyond the preview

Go deeper on X Med Ems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on X Med Ems.

Explore the full profile